top of page

Important Disclaimers
This article (the “Article”) is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any investment or any securities. This Article does not constitute investment advice and is not intended to be relied upon as the basis for an investment decision, and is not, and should not be assumed to be, complete. Readers should make their own investigations and evaluations of the information contained herein. The information contained herein does not take into account the particular investment objectives or financial circumstances of any specific person or entity who may receive it. Each reader should consult its own attorney, business adviser and tax adviser as to legal, business, tax and related matters concerning the information contained herein.  Except where otherwise indicated herein, the information provided herein is based on matters as they exist as of the date of preparation and not as of any future date and will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date of preparation. Certain information contained in this Article constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,”  “target,” “project,” “estimate,” “intend,” “continue” or “believe,” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. Readers should not rely on these forward-looking statements.  Certain information reflects subjective determinations which may prove to be incorrect. There can be no assurance that the estimates or projections will be accurate or that historical trends will continue. In considering the prior performance information contained herein, readers should bear in mind past performance is not necessarily indicative of future results. All rights reserved. The material may not be reproduced or distributed, in whole or in part, without the prior written permission of PrimeAlpha LLC.

Investing in the Future of Healthcare and Technology Innovations with Neal Mody at Zoic Capital

Neal Mody is the co-founder of two hard science companies collectively worth over $300M that have a real chance to be Unicorns, and the managing director of Zoic Capital, a venture capital firm, focused on commercializing companies that solve big health-related problems with cutting edge enabling technologies.

"I loved building stuff. So I asked myself, how do I build stuff with technology that has a chance to scale and truly affect the world? And the obvious answer to me was healthcare. I put together a thesis about healthcare and its sections where I thought they were low risk, potentially truly affecting all of humanity.

I decided to start my first business at 21 by opening a chain of retail stores. I sold them all at 24 and became a real estate investor because all of my best customers seemed like they're having the most fun in real estate. This was the time I got an opportunity to start a material science company in high-temperature superconductors. This was my introduction to the world of healthcare.

I later learned literally how to scale a company. Now having around 50 employees, 30 contractors, and around 2,700 unique patent claims, all of which were approved worldwide. We took the company to a hundred quarter million in value along with a new CEO who came in and is running it to a fair amount of success today.

I think my company in the future will enable Desktop MRIs at some point where if you feel a little injured after playing sports, we'll have an MRI guy come check you out, and you can order them via Uber and get the image almost instantly. After which, the telehealth consultation that follows will be easy and convenient.

There weren't enough investment dollars going to the med-tech field or even just beyond the med-tech fields at the early stage of interesting medical platform technologies. Such as the microbiome. Why wasn't there more money going into companies like that ten years ago? After realizing this, I spent several years studying venture capital and decided to build a deal flow before investing."

Zoic Capital Logo

Neal Mody, Managing Director

602 - 799 - 5575

Zoic invests in medtech and healthcare platforms with easy regulatory approval pathways and unique IP that will become standards of care.

Welcome to PrimeAlpha's interview series where we will share insights from industry practitioners discussing their journey and their discoveries.

Check us out on these platforms


Access PrimeAlpha Alternatives Education, Research, and Database of Managers and Investors
bottom of page